The company will also work with the University of Southampton and the Fondazione Edmund Mach – Centro Ricerca e Innovazione on the project
OptiBiotix Health has announced it will jointly fund a research project exploring the potential role its prebiotics and probiotics could have on sleep, stress and anxiety.
The project, which will be jointly funded by the Italian-based research institute Fondazione Edmund Mach, Centro Ricerca e Innovazione (‘FEM’) and the University of Southampton, will examine the impact of prebiotics such as SlimBiome and WellBiome, and probiotics like LPLDL on the human body during a period of stress-induced sleep disruption.
Stephen O’Hara, CEO of OptiBiotix, commented: “There is growing scientific evidence that indicates there is a relationship between the gastrointestinal microbiota, neurobiochemistry and emotional behaviour in humans. Recent findings have suggested that prebiotics, for example, can improve psychological or biological measures of depression, anxiety or stress.
“At OptiBiotix, we are excited to explore how our science-backed prebiotic and probiotic technologies positively impact the human microbiome in ways that haven’t yet been fully investigated. The industry-recognised ingredients SlimBiome and LPLDL, alongside our newly launched prebiotic blend, WellBiome, are superb candidates for this research project based on their previous demonstrative efficacy in human studies.”
The research will be carried out by a PhD student in the School of Human Development and Health in the Faculty of Medicine at the University of Southampton. As part of the agreement between OptiBiotix and both academic institutions, the project will include a double-blind, placebo controlled human study.
“The research carried out by the University of Southampton and FEM is a fundamental step for OptiBiotix as we move into 2021 and pursue next generation products,” said O’Hara. “Backed by our better science, better health ethos, this project will provide our global partners with the potential to drive new products in the health and wellbeing sector, opening up new commercial opportunities for SlimBiome, WellBiome and our probiotic, LPLDL.”